Читать книгу Protocols for High-Risk Pregnancies - Группа авторов - Страница 147

1 American College of Obstetricians and Gynecologists. ACOG Practice Bulletin No. 78: hemoglobinopathies in pregnancy. Obstet Gynecol 2007; 109(1):229–37.

2 Boafor TK, Olayemi E, Galadanci N, et al. Pregnancy outcomes in women with sickle‐cell disease in low and high income countries: a systematic review and meta‐analysis. Br J Obstet Gynaecol 2016; 123(5):691–8.

3 Brown JA, Sinkey RG, Steffensen TS, Louis‐Jacques AF, Louis JM. Neonatal abstinence syndrome among infants born to mothers with sickle cell hemoglobinopathies. Am J Perinatol 2020; 37:326–32.

4 Curtis KM, Tepper NK, Jatlaoui TC, et al. U.S. medical eligibility criteria for contraceptive use, 2016. MMWR Recommend Rep 2016; 65(3):1–103.

5 Howard J, Oteng‐Ntim E. The obstetric management of sickle cell disease. Best Pract Res Clin Obstet Gynaecol 2012; 26(1):25–36.

6 Kim DK, Hunter P. Advisory Committee on Immunization Practices recommended immunization schedule for adults aged 19 years or older – United States, 2019. MMWR 2019; 68(5):115–18.

7 National Institutes of Health. Evidence‐Based Management of Sickle Cell Disease, Expert Panel Report 2014. www.nhlbi.nih.gov/health‐topics/evidence‐based‐management‐sickle‐cell‐disease

8 Okusanya BO, Oladapo OT. Prophylactic versus selective blood transfusion for sickle cell disease in pregnancy. Cochrane Database Syst Rev 2016; 12:CD010378.

9 Oteng‐Ntim E, Meeks D, Seed PT, et al. Adverse maternal and perinatal outcomes in pregnant women with sickle cell disease: systematic review and meta‐analysis. Blood 2015; 125(21):3316–25.

10 Ware RE, de Montalembert M, Tshilolo L, Abboud MR. Sickle cell disease. Lancet 2017; 390(10091):311–23.